This medication is used in situations involving certain distressing symptoms of Parkinson's syndrome. This therapy is commonly used in situations involving certain distressing symptoms of Parkinson's syndrome, supporting the patient during difficult episodes by easing distress. It is commonly applied across conditions presenting with motor deficits where additional symptomatic support is needed.

The treatment is relevant in contexts involving heightened systemic burden, including conditions characterized by episodic or fluctuating manifestations such as Idiopathic Parkinson's disease, specific forms of secondary parkinsonism, and Restless Legs Syndrome (RLS).

“The primary goal of this therapy is to address the pronounced physical manifestations of the condition, helping patients cope more steadily with these difficult manifestations.”

The medication is applied in addressing symptom clusters that interfere with daily comfort, such as slowness of movement (bradykinesia), muscular rigidity (stiffness), and resting tremor. It helps address symptom clusters involving periods of increased severity, such as the re-emergence of symptoms ('wearing off') or severe early morning immobility (akinesia). This supportive benefit assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened discomfort.

---

Quick Fact: Relief for Motor Fluctuations

This medication is commonly used when symptoms become more noticeable during daily routines, applied in clinical settings that involve acute or unstable symptom patterns, which helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. Medsafe New Zealand Data Sheet

Official Eligibility and Non-Eligibility Information

Regulatory documentation defines strict patient eligibility for this medicine, primarily through a list of absolute restrictions and contraindications to prevent serious risk.

Eligibility Status	Population/Condition
Use is Allowed	Adults who have completed skeletal development (typically 25 years of age and older) and do not meet any of the exclusion criteria listed below.
Use is Contraindicated (Prohibited)	Patients under 25 years of age.
Use is Contraindicated (Prohibited)	Pregnant women and women of childbearing potential in the absence of adequate contraception.
Use is Contraindicated (Prohibited)	Known hypersensitivity to levodopa, benserazide, or any excipients.
Use is Contraindicated (Prohibited)	Concurrent treatment with non-selective monoamine oxidase (MAO) inhibitors.
Use is Contraindicated (Prohibited)	Closed-angle glaucoma.
Use is Contraindicated (Prohibited)	Decompensated (severe, uncontrolled) endocrine, renal (kidney), or hepatic (liver) function.
Use is Contraindicated (Prohibited)	Severe cardiac disorders (e.g., severe arrhythmias, cardiac failure).
Use is Contraindicated (Prohibited)	Psychiatric diseases with a psychotic component.
Use is Contraindicated (Prohibited)	History of, or suspected, malignant melanoma.

---

Summary of Eligibility Restrictions

Official labeling requires that patients must not have specific severe, systemic conditions, which are classified as contraindications (absolute prohibitions). The drug is strictly limited by age, as use is prohibited in those under 25 years old to ensure complete skeletal development. Furthermore, the use of this medicine is prohibited in women who are pregnant or of childbearing potential without adequate contraception. These rules define the essential constraints on who can safely receive this medicine based on official governmental regulatory standards.

The official regulatory profile for Мадопар (Levodopa/Benserazide) establishes specific constraints and prohibitions based on documented interaction patterns with other medicines and products.

Formal Contraindications: Co-administration with non-selective Monoamine Oxidase (MAO) inhibitors is strictly prohibited, as this combination carries a risk of severe hypertensive crisis. The drug is also formally contraindicated with the anesthetic Halothane, necessitating discontinuation 12 to 48 hours before general anesthesia to avoid cardiac and blood pressure fluctuations.

Pharmacodynamic Interference: Cautions are documented for co-administration with antihypertensive agents, as this may potentiate the risk of orthostatic hypotension. Sympathomimetic substances are noted for their potential to have their physiological effects enhanced. Certain dopamine receptor antagonists, including some antipsychotic drugs and opioids, may formally antagonize or counteract the intended effects of Мадопар.

Exposure and Timing Constraints: The systemic exposure of levodopa is sensitive to co-administered substances and dietary intake. Iron Sulfate is documented to reduce the overall systemic exposure, including the maximum plasma concentration ( C max) and Area Under the Curve (AUC). To manage competition for absorption from protein-rich meals, standard formulations must be separated in time (at least 30 minutes before or 1 hour after meals). Additionally, initiating therapy with a COMT inhibitor requires an official adjustment to the Мадопар dosage due to altered metabolism.

How Мадопар Works: Mechanism of Action

The mechanism of Мадопар (Levodopa/Benserazide) is based on a coordinated two-part system designed to augment dopaminergic signaling in the central nervous system (CNS).

---

Peripheral Protection and Targeted Delivery

This domain covers the role of Benserazide, a reversible competitive enzyme inhibitor that blocks peripheral L-amino acid decarboxylase (AADC). By preventing the breakdown of the Levodopa pro-drug outside the brain, this mechanism ensures maximal transport of the precursor across the blood-brain barrier (BBB), leading to a higher availability of the substrate for central conversion.

---

Central Conversion and Neurotransmitter Augmentation

Once delivered centrally, the mechanism relies on Levodopa being rapidly converted by AADC within the remaining functional neurons into the active neurotransmitter, dopamine . The resulting increased availability of dopamine activates post-synaptic dopamine receptors in the basal ganglia, thereby augmenting neurochemical signaling and modulating the activity patterns within the motor control loop.

How to Use Madopar (Levodopa/Benserazide)

Madopar is administered orally and is available in forms including standard and dispersible tablets and hard and prolonged-release capsules. All dosage forms contain Levodopa and Benserazide in a 4:1 ratio.

Dosing and Schedule Principles

Administration follows a structured approach that begins with a low initial dose (e.g., 50 mg/12.5 mg or 100 mg/25 mg three to four times daily). The daily dosage must be divided into at least three doses. The dose is then gradually increased (titrated) until the optimal therapeutic regimen is achieved, typically occurring at weekly intervals. The maximum dose rarely exceeds 1000 mg of Levodopa per day. Treatment is considered long-term, requiring continuation for at least six months before concluding failure to respond.

Administration Conditions

Condition	Instruction
Timing (Standard/Dispersible)	Take 30 minutes before or 1 hour after a meal to minimize protein interference.
Timing (Prolonged-Release)	Generally taken with or immediately after meals.
Food Restriction	Intake must avoid high-protein foods to ensure proper absorption.
Capsule/CR Handling	Must be swallowed whole; do not open or crush.
Dispersible Tablet Prep	Dissolve in a small amount of water (25 mL to 50 mL) and consume within 30 minutes.

Population-Specific Rules

Madopar is not administered to patients under 25 years of age. For older adults, a lower starting dose and a slower rate of titration may be applied. If a dose is missed, skip the missed dose and take the next dose at the scheduled time; do not take a double dose.

Research Evidence / Overview of Studies for Madopar

---

Research Evidence for Idiopathic Parkinson's Disease (PD)

The core research for Levodopa/Benserazide is based on a foundation of Randomized Controlled Trials (RCTs) and subsequent systematic reviews applied in trials exploring how symptoms change over time. Research examined motor symptoms—such as slowness of movement, stiffness, and tremor—using standardized scales, as well as outcomes reflecting daily functioning or activity level. These studies included patients newly diagnosed with PD as well as those with more moderate or advanced disease.

Research findings describe patterns observed in the studies, where participants reported changes in their motor function across the defined trial periods. Evidence contributes to understanding symptom patterns and includes data collected to document the periods when patients experienced good function, known as "On" time, versus periods of increased symptom activity, or "Off" time. The data accumulated from these trials form a well-documented clinical reference profile.

Despite its long history of use, research highlights that long-term outcomes, particularly the development of motor complications (uncontrolled movements or fluctuations), are not fully characterized over many years. Researchers continue to monitor how these complex functional outcomes evolve beyond the initial, shorter trial periods.

---

Research Evidence for Managing Motor Fluctuations

Studies explored the combination's use when symptoms become more noticeable during daily routines, particularly in patients who experience the phenomenon of end-of-dose deterioration (known as the "wearing off" effect) or severe early morning immobility. Research has explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. These studies monitored outcomes describing episodic or acute changes, such as the frequency and duration of "Off" periods.

When studying the dispersible tablet form, research provided insight into short-term changes, documenting how quickly observable action was measured after administration, which is relevant in trials assessing short-term or episodic symptom patterns. Findings indicate patterns of change measured during the study period, showing a shift in the documented time-course of patient motor stability, specifically patterns where daily "Off" time was documented to decrease.

---

Research Evidence for Restless Legs Syndrome (RLS)

Levodopa/Benserazide was evaluated in numerous short-term RCTs and meta-analyses in populations with RLS. Research examined outcomes related to physical discomfort, such as the severity of RLS symptoms, alongside objective and subjective sleep quality measures. The study outcomes examined focused on patient-reported outcomes describing perceived discomfort.

Studies reported how symptoms evolved in the observed populations during the short trial periods. Research highlights changes measured during the study period, including descriptions of reduced RLS symptom scores and patterns of improved subjective sleep quality. Findings help contextualize how patients reported their experience and contribute to the broader evidence landscape for this condition.

Key Studies & References

1. NEW ZEALAND DATA SHEET Madopar (Levodopa + benserazide) - Regulatory Monograph and Indications
2. AUSTRALIAN PRODUCT INFORMATION Madopar (levodopa and benserazide hydrochloride)
3. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients
4. Study Details | NCT00144209 | Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

Common questions about Мадопар (FAQ)

---

Q: How quickly should I expect to feel the effects of Мадопар after starting treatment?

Official regulatory information notes that the dispersible tablet form is suited for when a more rapid onset of action is required. This form is often used in scenarios where a quicker onset of action may be beneficial, such as managing early morning symptoms.

Q: Is Мадопар used for conditions other than Parkinson's disease?

Yes, according to official regulatory documents, in addition to treating Parkinson's disease, Madopar is also formally indicated for the symptomatic treatment of Restless Legs Syndrome (RLS).

Q: What are the most common side effects people report when taking Мадопар?

The official product information states that two commonly reported side effects include dyskinesia (involuntary, uncontrolled movements) and gastrointestinal issues. Nausea and vomiting are specifically noted as common, especially when treatment is first started or when the dose is being adjusted.

Q: Can Мадопар cause issues with sleep or insomnia?

Yes, official documents list insomnia (difficulty sleeping) and other sleep disorders as common adverse reactions. Sudden onset of sleep has also been reported, which is included in the safety documentation.

Q: Is it normal to feel dizzy when first starting Мадопар?

Dizziness is listed as a potential adverse reaction in official product information. This is often related to a side effect called orthostatic hypotension, which is a drop in blood pressure that occurs when a person stands up quickly. These effects have been noted to occur, particularly in the initial phases of therapy.

Q: Are there any major dietary restrictions I need to know about while on Мадопар?

Yes, the absorption of Madopar can be significantly reduced by high-protein meals, and regulatory documents advise separating the drug administration from these meals. Official information also notes that supplements containing Iron Sulfate should be separated in time from Madopar, as iron reduces the amount of the active ingredient that is absorbed.

Q: Are there any vitamins or supplements that interact with Мадопар?

High doses of Pyridoxine (Vitamin B6) are noted in official information due to the potential to reduce the effectiveness of the medication. While the inhibitor in Madopar (benserazide) is designed to minimize this effect, caution regarding high B6 intake is part of the product information.

Q: What are the signs of a serious, but rare, side effect from Мадопар?

Serious, but rare, adverse events include significant changes in your blood count (known as blood dyscrasias). Another risk is Neuroleptic Malignant Syndrome (NMS), a condition characterized by symptoms like very high fever, muscle rigidity, and changes in mental state.

Q: Can taking Мадопар affect my blood pressure?

Yes, Madopar can affect blood pressure. Regulatory documents list orthostatic hypotension (a drop in blood pressure when standing) as a potential side effect. This is a potential safety consideration for individuals with a history of heart conditions or blood pressure issues.

Q: Does Мадопар require special storage instructions?

Yes. According to official guidelines, Madopar must be stored in its original container with the cap tightly closed to protect it from moisture and humidity, as the contents are sensitive. It should also be stored at a temperature that does not exceed 25^circC.

Q: Is it normal for my urine color to change while on Мадопар?

Yes, a change in body fluid color can occur. The active ingredient levodopa may cause urine, sweat, or saliva to become reddish-brown or darker. This discoloration is generally noted in official information as an expected, non-harmful finding.

Q: Does Мадопар affect my ability to concentrate?

The official product information lists adverse reactions that could impact concentration, including confusion and the potential for sedation or episodes of sudden sleepiness. These conditions are described in regulatory documents as adverse reactions that could impact a patient's ability to concentrate.

Q: What evidence supports the use of Мадопар for treating restless legs syndrome?

Regulatory documents confirm that the medicine is supported by evidence from clinical trials and is officially indicated for the symptomatic treatment of Restless Legs Syndrome (RLS).

Q: Can Мадопар be prescribed for essential tremor?

According to the official prescribing information, Essential Tremor is not an approved indication for the use of Madopar.

Q: What is the half-life of Мадопар in the body?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. Official pharmacokinetic data indicates that the half-life of levodopa, when combined with benserazide, is approximately 1.5 hours, though this can be longer for modified-release forms.

Q: Do people with heart conditions need to be careful with Мадопар?

Official product information notes caution is required. Madopar is contraindicated (prohibited) for patients with severe cardiac disorders. It should be used carefully in those with a history of cardiac arrhythmias or coronary artery disease.

Q: Can Мадопар interact with common cold or flu medicines?

Caution is advised. Many over-the-counter cold and flu preparations contain sympathomimetic agents. The official drug label indicates that Madopar can potentiate (enhance) the effects of these agents.

How to Store and Dispose of Madopar (Levodopa/Benserazide)

The official storage and disposal requirements for Madopar are defined by regulatory labeling to maintain stability and prevent environmental contamination.

Mandatory Storage Conditions

Requirement	Specification
Temperature	Do not store above 25 C.
Protection	Store in a cool, dry place away from direct sunlight.
Packaging	Keep the bottle/cap tightly closed to protect the hygroscopic contents from moisture.
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Madopar via household waste or wastewater (e.g., sink or toilet). Regulatory guidance requires that medicines be returned to a pharmacist or a recognized collection program to ensure proper disposal and environmental protection. Disposal must comply with national and local laws.